Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artemether-lumefantrine versus artesunate-amodiaquine for uncomplicated Plasmodium falciparum malaria in children in Ouesso
PACTR201905606150545Phase 4Not yet recruiting
- Sponsor
- Ministry of Public Health, Hygiene and Prevention of the Democratic Republic of the Congo
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of artemether, lumefantrine, artesunate and amodiaquine in Malaria (2 arms), sponsored by Ministry of Public Health, Hygiene and Prevention of the Democratic Republic of the Congo. Primary endpoint: Percent of treatment failures. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
artemetherlumefantrineartesunateamodiaquine
03
Conditions
Malaria
Beyond the preview
Go deeper on PACTR201905606150545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201905606150545.